Agomab Therapeutics NV is headquartered at Posthoflei 1/6, 2600 Antwerpen, Belgium.
Agomab was founded in 2017.
Agomab is traded on the NASDAQ Global Select Market under the ticker symbol AGMB.
00860C102
Agomab began trading on the NASDAQ Global Market on February 6, 2026.
Agomab’s fiscal year-end is December 31.
Agomab is incorporated under Belgian law.
Agomab’s American Depositary Shares (ADSs) (representing common shares) can be purchased through a financial services provider of your choice. Agomab does not have a direct stock purchase plan.
Agomab currently does not pay dividends or offer a dividend reinvestment program.
The depositary bank for Agomab’s ADR facility is The Bank of New York Mellon. Computershare acts as transfer agent in the US for Agomab’s American Depositary Receipts.
Agomab’s independent auditor is PwC Bedrijfsrevisoren BV / Reviseurs d’Entreprises SRL.
The Agomab press release archives can be accessed via the News Page.
Alerts can be set up from the “email alerts” section of the “Investors” page.
The Agomab SEC filings can be accessed from the “SEC filings” section of the “Investors” page or www.sec.gov.
Please email us at ir@agomab.com
Online at Whistleblower Hotline or via phone at 0800 89 326 (Belgium) or +1 (669) 288 7154 (United States), by entering the Agomab organization code (125405).